Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Matthias Weiss, MD, PhD, Susanna Jacobus, MS, Lynne I Wagner, PhD, David Cella, PhD, Michael S Katz, BS., MBA, Vincent Rajkumar, MD, Rafael Fonseca, MD

Blood (2011) 118 (21): 4184.

https://doi.org/10.1182/blood.V118.21.4184.4184

Published: 2011

Journal Articles

Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial

David Samuel diCapua Siegel, MD, PhD, Susanna Jacobus, MS, S. Vincent Rajkumar, MD, Rafat Abonour, MD, Natalie Scott Callander, MD, Michael S Katz, BS., MBA, Rafael Fonseca, David H. Vesole, MD, PhD, On behalf of the Eastern Cooperative Oncology Group

Blood (2010) 116 (21): 38.

https://doi.org/10.1182/blood.V116.21.38.38

Published: 2010

Journal Articles

Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study

David H. Vesole, MD, PhD, Martin M Oken, MD, Charles Heckler, Philip R. Greipp, MD, Michael S Katz, BS., MBA, Susanna Jacobus, MS, Gary R Morrow, PhD, MS, On Behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group

Blood (2010) 116 (21): 3017.

https://doi.org/10.1182/blood.V116.21.3017.3017

Published: 2010

Journal Articles

Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)

David H. Vesole, MD, PhD, Susanna Jacobus, MS, S. Vincent Rajkumar, MD, Rafat Abonour, MD, Natalie Scott Callander, MD, Philip R. Greipp, MD, Rafael Fonseca, Michael S Katz, BS., MBA, David Samuel diCapua Siegel, MD, PhD, On Behalf of the Eastern Cooperative Oncology Group

Blood (2010) 116 (21): 308.

https://doi.org/10.1182/blood.V116.21.308.308

Published: 2010

Journal Articles

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, PhD, Michael Williams, MD, Rafat Abonour, MD, David Siegel, MD, Philip Greipp, MD

Blood (2007) 110 (11): 74.

https://doi.org/10.1182/blood.V110.11.74.74

Published: 2007

Journal Articles

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, Philip Greipp, MD

Blood (2006) 108 (11): 799.

https://doi.org/10.1182/blood.V108.11.799.799

Published: 2006

NARROW

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial

Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study

Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

Email alerts

ASH Publications

American Society of Hematology

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial

Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study

Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only